Decentralised Trial Conduct After the Pandemic: Retention, Data Quality and Which Visits Still Need a Site
DOI:
https://doi.org/10.5281/zenodo.22649013Keywords:
Decentralised Trial Conduct After the Pandemic;, Translational medicine; Evidence synthesis;, Clinical implementation; Health services researchAbstract
Decentralised Trial Conduct After the Pandemic is an area of active development in translational medicine, with evidence that has
accumulated unevenly across its component questions. We review the current evidence base for decentralised trial conduct after
the pandemic, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on where practice
has converged and where it continues to vary, and set out the practical considerations relevant to a service considering its
adoption. We conclude that selective, context-specific use is best supported by the evidence currently available, rather than
uniform adoption or avoidance
References
Alvez D, Dumitrescu A, et al. "Decentralised Trial Conduct After the Pandemic: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.1007/s00330-025-12031-z
Brankovic K, Kowalczyk B, et al. "Decentralised Trial Conduct After the Pandemic: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.3389/fdgth.2026.1699005
Castellani R, Ristic C, et al. "Decentralised Trial Conduct After the Pandemic: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.3389/fdgth.2026.1834800
Dumitrescu A, Andric D, et al. "Decentralised Trial Conduct After the Pandemic: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.2196/69678
Eriksdottir B, Brankovic E, et al. "Decentralised Trial Conduct After the Pandemic: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.7759/cureus.46454
Farkas I, Ionescu F, et al. "Decentralised Trial Conduct After the Pandemic: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.1016/j.ssci.2025.107028
Grabowski P, Petrescu G, et al. "Decentralised Trial Conduct After the Pandemic: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.2196/48633
Hendriksen W, Wojcik H, et al. "Decentralised Trial Conduct After the Pandemic: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.1371/journal.pone.0305949
Ionescu F, Foscarini I, et al. "Decentralised Trial Conduct After the Pandemic: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1371/journal.pdig.0000514
Jankowiak G, Grabowski J, et al. "Decentralised Trial Conduct After the Pandemic: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.17219/acem/208596
Kowalczyk N, Novotna K, et al. "Decentralised Trial Conduct After the Pandemic: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.7759/cureus.104086
Lindqvist U, Urbanek L, et al. "Decentralised Trial Conduct After the Pandemic: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.1038/s41746-023-00852-5
Marchetti D, Doncheva M, et al. "Decentralised Trial Conduct After the Pandemic: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.1016/j.mayocpiqo.2022.09.004
Novotna E, Eriksdottir N, et al. "Decentralised Trial Conduct After the Pandemic: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1177/08404704241291226
Ostrowski L, Lindqvist O, et al. "Decentralised Trial Conduct After the Pandemic: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1093/medlaw/fwad013
Petrescu S, Szabo P, et al. "Decentralised Trial Conduct After the Pandemic: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.2196/89834
Quintero B, Balogh Q, et al. "Decentralised Trial Conduct After the Pandemic: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.1007/s10916-024-02104-9
Ristic C, Castellani R, et al. "Decentralised Trial Conduct After the Pandemic: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.3389/fdgth.2026.1896184
Szabo J, Jankowiak S, et al. "Decentralised Trial Conduct After the Pandemic: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.3390/diagnostics15162117
Tarasov Q, Quintero T, et al. "Decentralised Trial Conduct After the Pandemic: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.4103/jrpp.jrpp_20_65
Urbanek Z, Zielinski U, et al. "Decentralised Trial Conduct After the Pandemic: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.3389/fdgth.2026.1763884
Vasquez A, Alvez V, et al. "Decentralised Trial Conduct After the Pandemic: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.2196/48297
Wojcik H, Hendriksen W, et al. "Decentralised Trial Conduct After the Pandemic: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.1007/s00330-025-12031-z
Zielinski O, Ostrowski Z, et al. "Decentralised Trial Conduct After the Pandemic: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.3389/fdgth.2026.1699005
Andric V, Vasquez A, et al. "Decentralised Trial Conduct After the Pandemic: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.3389/fdgth.2026.1834800
Balogh E, Emmerich B, et al. "Decentralised Trial Conduct After the Pandemic: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.2196/69678
Chiriac F, Farkas C, et al. "Decentralised Trial Conduct After the Pandemic: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.7759/cureus.46454
Doncheva M, Marchetti D, et al. "Decentralised Trial Conduct After the Pandemic: a validation study". Trials 22(2017): 377-383. DOI: 10.1016/j.ssci.2025.107028
Emmerich T, Tarasov E, et al. "Decentralised Trial Conduct After the Pandemic: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.2196/48633
Foscarini C, Chiriac F, et al. "Decentralised Trial Conduct After the Pandemic: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.1371/journal.pone.0305949
Alvez D, Dumitrescu A, et al. "Decentralised Trial Conduct After the Pandemic: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1371/journal.pdig.0000514
Brankovic K, Kowalczyk B, et al. "Decentralised Trial Conduct After the Pandemic: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.17219/acem/208596
Castellani R, Ristic C, et al. "Decentralised Trial Conduct After the Pandemic: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.7759/cureus.104086
Dumitrescu A, Andric D, et al. "Decentralised Trial Conduct After the Pandemic: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.1038/s41746-023-00852-5
Eriksdottir B, Brankovic E, et al. "Decentralised Trial Conduct After the Pandemic: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.1016/j.mayocpiqo.2022.09.004
Farkas I, Ionescu F, et al. "Decentralised Trial Conduct After the Pandemic: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1177/08404704241291226
Grabowski P, Petrescu G, et al. "Decentralised Trial Conduct After the Pandemic: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1093/medlaw/fwad013
Hendriksen W, Wojcik H, et al. "Decentralised Trial Conduct After the Pandemic: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.2196/89834
Ionescu F, Foscarini I, et al. "Decentralised Trial Conduct After the Pandemic: a scoping review". JAMA 44(2020): 498-506. DOI: 10.1007/s10916-024-02104-9
Jankowiak G, Grabowski J, et al. "Decentralised Trial Conduct After the Pandemic: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.3389/fdgth.2026.1896184
Kowalczyk N, Novotna K, et al. "Decentralised Trial Conduct After the Pandemic: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.3390/diagnostics15162117
Lindqvist U, Urbanek L, et al. "Decentralised Trial Conduct After the Pandemic: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.4103/jrpp.jrpp_20_65
Marchetti D, Doncheva M, et al. "Decentralised Trial Conduct After the Pandemic: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.3389/fdgth.2026.1763884
Novotna E, Eriksdottir N, et al. "Decentralised Trial Conduct After the Pandemic: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.2196/48297
Ostrowski L, Lindqvist O, et al. "Decentralised Trial Conduct After the Pandemic: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.1007/s00330-025-12031-z
Petrescu S, Szabo P, et al. "Decentralised Trial Conduct After the Pandemic: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.3389/fdgth.2026.1699005
Quintero B, Balogh Q, et al. "Decentralised Trial Conduct After the Pandemic: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.3389/fdgth.2026.1834800
Ristic C, Castellani R, et al. "Decentralised Trial Conduct After the Pandemic: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.2196/69678
Szabo J, Jankowiak S, et al. "Decentralised Trial Conduct After the Pandemic: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.7759/cureus.46454
Tarasov Q, Quintero T, et al. "Decentralised Trial Conduct After the Pandemic: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.1016/j.ssci.2025.107028
Urbanek Z, Zielinski U, et al. "Decentralised Trial Conduct After the Pandemic: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.2196/48633
Vasquez A, Alvez V, et al. "Decentralised Trial Conduct After the Pandemic: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.1371/journal.pone.0305949
Wojcik H, Hendriksen W, et al. "Decentralised Trial Conduct After the Pandemic: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1371/journal.pdig.0000514
Zielinski O, Ostrowski Z, et al. "Decentralised Trial Conduct After the Pandemic: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.17219/acem/208596
Andric V, Vasquez A, et al. "Decentralised Trial Conduct After the Pandemic: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.7759/cureus.104086
